-
Mashup Score: 10Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen - 5 month(s) ago
npj Vaccines – Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen
Source: www.nature.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 51
KEYTRUDA® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in OS as a neoadjuvant and adjuvant treatment versus pre-operative chemotherapy for NSCLC Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) met its dual primary endpoint of overall survival (OS). At a pre-specified interim analysis, KEYTRUDA plus chemotherapy before surgery (neoadjuvant), followed by resection and KEYTRUDA as a single agent after surgery (adjuvant), demonstrated a statistically significant and clinically meaningful improvement in OS compared to neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients. The safety profile of KEYTRUDA was consistent with that observed in previously
Source: www.merck.comCategories: Hem/Oncs, Latest HeadlinesTweet-
JUST IN: KEYNOTE-671 OS + for EFS AND OS!!!! -NSCLC Stage II, IIIA or IIIB (T3-4N2) -Pembrolizumab is the first PD1 drug with OS in a perioperative setting! -Initially presented at #ASCO23 -Update at #ESMO23 https://t.co/rvGAQCu1yI @OncoAlert @myESMO @OncBrothers https://t.co/unbjYU8Atv https://t.co/vGyoOx3Oh4
-
🔥@OncoAlert Hot off the press Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival. 👇🏼 https://t.co/gJtIzuB4xV https://t.co/CPDSHjQwOg
-
-
Mashup Score: 0
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 5
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy - 7 month(s) ago
Author links open overlay panel Teresa Amaral MD, PhD a b, Oltin Tiberiu Pop MD, PhD c, Eftychia Chatziioannou MD a, Tobias Sinnberg Dr rer nat a b d, Heike Niessner Dr rer nat a b, Jing Zhao MSc e, Sandra Stephanie Ring PhD f, Markus Joerger MD, PhD g, Christopher Schroeder MD h, Sorin Armeanu-Ebinger Dr rer nat h, Antonio Cozzio MD, Dr sc nat i, Ulrike Leiter MD a, Ioannis Thomas MD a, Wolfram Jochum MD j, Claus Garbe MD a, Stephan Forchhammer MD a, Mitchell Levesque PhD k, Joanna Mangana MD k, Michael
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read this article to earn #CME Credit: A team of researchers designed a research study to help determine the effectiveness of #adjuvant #chemotherapy after #neoadjuvant chemotherapy (NAC) followed by surgery specifically for #PDAC patients. Learn more: https://t.co/lceRkR1Xim https://t.co/XQFFRyLci7
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read this article to earn #CME Credit: A team of researchers designed a research study to help determine the effectiveness of #adjuvant #chemotherapy after #neoadjuvant chemotherapy (NAC) followed by surgery specifically for #PDAC patients. Learn more: https://t.co/lceRkR1Xim https://t.co/PIA8s2VSZD
-
-
Mashup Score: 0Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy - 1 year(s) ago
This pilot study examined how patients make the decision of whether or not to undergo adjuvant anti-PD1 immunotherapy when made aware of quantitative risks and
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet
Investigators conducting human in vitro modeling of #adjuvant 💉 formulations of unformulated, oil-in-water, and liposomal delivery platforms, demonstrating the enhancement of immune responses to SARS-CoV-2 antigen. https://t.co/oQxflW0HHV https://t.co/JqXpXhWqRQ